Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSD1UN)

• Drug Name: Bevacizumab Drug Info
• Synonyms: Bevacizumab (ophthalmic slow-release tissue tablet)

Indication

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[1]
Adult acute monocytic leukemia		Approved	[2]
Biliary tract cancer	2C17	Approved	[3]
Childhood acute megakaryoblastic leukemia		Approved	[2]
Cholangiocarcinoma	2C12.10	Approved	[4]
Colon adenocarcinoma		Approved	[5]
Colorectal carcinoma		Approved	[6]
Esophageal disorder		Approved	[7]
Glioblastoma	2A00	Approved	[8]
Glioblastoma of brain	2A00.00	Approved	[9]
Hemangioblastoma		Approved	[10]
Intracranial meningioma		Approved	[11]
Lung adenocarcinoma		Approved	[12]
Malignant epithelial tumor of ovary		Approved	[13]
Metastatic colorectal cancer	2B91	Approved	[14]
Non-small-cell lung cancer	2C25.Y	Approved	[15]
Rectal adenocarcinoma	2B92	Approved	[16]
Von hippel-lindau disease	5A75	Approved	[17]
Colorectal cancer	2B91.Z	Phase 3	[18]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[19]
Brain metastases	2D50	Phase 2	[18]
Lung cancer	2C25.0	Phase 1	[18]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
Ovarian cancer	2C73	Application submitted	[20]
Adult glioblastoma		Investigative	[21]
Colon cancer	2B90.Z	Investigative	[22]
Fallopian tube cancer	2C74	Investigative	[23]
Hereditary hemorrhagic telangiectasia	LA90.00	Investigative	[24]
Lung large cell carcinoma		Investigative	[25]

• Cross-matching ID: TTD Drug ID: DMSD1UN

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[14]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[28]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[29]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[30]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[31]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[32]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[33]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[34]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[35]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[20]

Drug(s) Affected By Mastermind-like protein 2 (MAML2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[36]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[37]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[40]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[41]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[42]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[43]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[44]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[45]

Drug(s) Affected By 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[47]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[48]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[49]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[37]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[51]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[52]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[53]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[48]

Drug(s) Affected By TGF-beta receptor type-2 (TGFBR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[54]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[55]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[56]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[58]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[62]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[62]

Drug(s) Affected By Beta-parvin (PARVB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[63]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[41]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[64]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[65]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[66]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[67]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[68]

Drug(s) Affected By Mitochondrial peptide methionine sulfoxide reductase (MSRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[51]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[70]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[71]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[41]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[73]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[74]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[75]

Drug(s) Affected By Synaptic vesicle glycoprotein 2C (SV2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[41]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[44]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[45]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[66]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[45]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[26]
HUMAN vascular endothelial growth factor (VEGF)	TT140V6	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Inhibitor	[19]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)	OT25JBA3	F263_HUMAN	Drug Response	[27]
Beta-parvin (PARVB)	OT9OGVWX	PARVB_HUMAN	Drug Response	[27]
Mastermind-like protein 2 (MAML2)	OT1TSVAR	MAML2_HUMAN	Drug Response	[27]
Mitochondrial peptide methionine sulfoxide reductase (MSRA)	OTBS15SD	MSRA_HUMAN	Drug Response	[27]
Synaptic vesicle glycoprotein 2C (SV2C)	OTIH108W	SV2C_HUMAN	Drug Response	[27]
TGF-beta receptor type-2 (TGFBR2)	OT3P7GZP	TGFR2_HUMAN	Drug Response	[27]

References

• [1] Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis. Rare Tumors. 2019 May 14;11:2036361318825413.
• [2] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [3] Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opin Investig Drugs. 2021 Apr;30(4):411-418.
• [4] Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541-565.
• [5] Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer. Immunotherapy. 2023 Feb;15(3):127-133.
• [6] Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508.
• [7] Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020 Oct 7;5(1):229.
• [8] Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.
• [9] Synchronous glioblastoma and brain metastases: illustrative case. J Neurosurg Case Lessons. 2022 Mar 21;3(12):CASE21714.
• [10] Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma. Cureus. 2022 Dec 17;14(12):e32624.
• [11] The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review. Expert Rev Anticancer Ther. 2020 Mar;20(3):197-203.
• [12] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85.
• [13] Gynecologic cancer in pregnancy. Gynecol Oncol. 2020 Jun;157(3):799-809.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.
• [16] Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as?preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term?results. BMC Cancer. 2020 Nov 27;20(1):1164.
• [17] 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. J Nucl Med. 2016 Aug;57(8):1244-50.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954-1963.
• [22] Colon cancer. Crit Rev Oncol Hematol. 2010 May;74(2):106-33.
• [23] OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45.
• [24] Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018 Sep;103(9):1433-1443.
• [25] Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94.
• [26] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [27] Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 9;111(6):1241-8. doi: 10.1038/bjc.2014.430. Epub 2014 Aug 12.
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [29] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [30] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [31] Clinical pipeline report, company report or official report of Genentech (2009).
• [32] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [33] Bispecific antibodies and their applications
• [34] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [35] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [36] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [37] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [38] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [39] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [40] Real-time monitoring of cisplatin-induced cell death. PLoS One. 2011;6(5):e19714. doi: 10.1371/journal.pone.0019714. Epub 2011 May 16.
• [41] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [42] Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 2006 Mar 1;66(5):2765-77.
• [43] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [44] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [45] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [46] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [47] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [48] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [49] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [50] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [51] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [52] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [53] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [54] Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology. 2009 Mar 4;257(1-2):10-6. doi: 10.1016/j.tox.2008.12.002. Epub 2008 Dec 9.
• [55] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [56] Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors. Clin Rheumatol. 2014 Dec;33(12):1815-21. doi: 10.1007/s10067-014-2807-8. Epub 2014 Oct 24.
• [57] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [58] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [59] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [60] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [61] Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin. 2003 Jul;24(7):646-50.
• [62] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [63] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [64] NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.
• [65] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [66] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [67] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [68] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [69] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [70] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [71] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [72] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [73] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [74] Resveratrol preconditioning increases methionine sulfoxide reductases A expression and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem. 2013 Jun;24(6):1070-7. doi: 10.1016/j.jnutbio.2012.08.005. Epub 2012 Sep 28.
• [75] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [76] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.